Science research – Scientific Library http://scientific-library.net/ Sun, 09 Jan 2022 13:10:46 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://scientific-library.net/wp-content/uploads/2021/11/cropped-icon-32x32.png Science research – Scientific Library http://scientific-library.net/ 32 32 America’s Best Universities for Social Science Research https://scientific-library.net/americas-best-universities-for-social-science-research/ Sun, 09 Jan 2022 11:00:00 +0000 https://scientific-library.net/americas-best-universities-for-social-science-research/

In an age when many of our most pressing problems involve models of human behavior, the role of the social sciences has become increasingly vital. Whether it is the spread of disinformation and conspiracy theories, a growing mistrust of institutions, the proliferation of intergroup conflicts, the rise of undemocratic ideology, the causes and consequences poverty or the spread of preventable diseases, social science research is a crucial source for understanding and solving these problems.

Where is cutting-edge social science research conducted in the United States? What are our top universities for research in areas such as anthropology, economics, political science, psychology, and sociology.

An answer to this question can be found in the Higher Education Research and Development Survey (HERD), recently published by the National Science Foundation (NSF). This survey measures the dollars spent each year on research and development (R&D) at US colleges and universities.

The latest HERD survey, sponsored by the National Center for Science and Engineering Statistics of the National Science Foundation, presents data on R&D spending for fiscal year 2020, collected from 915 universities and colleges that award bachelor’s degrees or above and have spent at least $ 150,000 on R&D in the previous fiscal year.

The HERD survey summarizes the federal, state, and other funds that a university spends on all of its research activities, and it also divides these expenditures into ten main areas: computer and information science; engineering; geosciences, atmospheric sciences and ocean sciences; life sciences; mathematics and statistics; physical science; psychology; Social Sciences; other sciences; and non-science and engineering.

Here are the top ten universities ranked by research expenditure in each of the five social science disciplines plus one miscellaneous social science category (My thanks to Michael Crow, president of Arizona State University and Katie Paquet, senior advisor for strategic communications to ASU for providing tabular breakdowns of these data The full set of data tables and technical information from the HERD survey can be found here.)

Anthropology

In fiscal 2020, universities in the United States spent a total of $ 119. 3 million for research in anthropology. The top ten institutions were (figures are in millions of dollars):

Arizona State University $ 14.9

University of Michigan $ 6.2

University of South Carolina $ 4.8

University of Buffalo (SUNY) $ 4.0

Texas A&M University $ 4.0

University of Oklahoma $ 4.0

University of Arizona $ 3.4

University of Wisconsin-Milwaukee $ 2.8

University of Tennessee $ 2.5

Colorado State University $ 2.4

Economy

In fiscal 2020, US universities spent a total of $ 562.2 million on research in economics. The top ten institutions were (in millions of dollars):

George Mason University $ 55.0

Harvard University $ 33.6

University of California, Berkeley $ 31.7

University of Michigan $ 31.1

Massachusetts Institute of Technology $ 30.8

University of Michigan $ 22.8

College of Teachers, Columbia University $ 12.1

Purdue University $ 11.0

Georgia State University $ 11.0

University of California, Davis $ 10.2

Psychology

A total of $ 1.36 billion was spent on psychology research in fiscal year 2020. The top ten universities were (in millions of dollars):

University of North Carolina at Chapel Hill $ 41.7

Pennsylvania State University $ 40.6

Florida International University $ 34.6

University of Minnesota $ 31.9

New York University $ 28.5

University of Georgia $ 25.8

University of Connecticut $ 21.6

Boston university $ 20.4

University of Michigan $ 20.4

San Diego State University $ 20.2

Political science and government

A total of $ 425.3 million was spent in these areas in FY2020. The top ten institutions (in millions of dollars spent) were:

Harvard University $ 41.8

Georgetown University $ 31.8

Princeton University $ 27.5

University of Michigan, Ann Arbor $ 25.5

Arizona State University $ 16.6

University of California, San Diego $ 12.8

University of Albany (SUNY) $ 12.4

Indiana University $ 12.2

University of California, Berkeley $ 9.4

Indiana University-Purdue University, Indianapolis $ 7.8

Sociology Demography and demographic studies

University spending for research in these areas totaled $ 591.8 million in FY2020. The top ten institutions were (in $ millions):

University of North Carolina at Chapel Hill $ 66.6

Indiana University $ 10.9

University of Colorado $ 10.3

duke university $ 10.3

University of Nebraska-Lincoln $ 9.9

Purdue University $ 9.3

Cornell University $ 9.2

Columbia university $ 9.1

New York University $ 7.6

Indiana University-Purdue University, Indianapolis $ 7.4

Other social sciences

Fiscal 2020 research spending in a range of other areas of the social sciences such as criminology, geography and public policy exceeded $ 1.2 billion. The top ten universities in this miscellaneous category were:

University of Michigan $ 99.0

Harvard University $ 62.9

University of Southern California $ 57.2

University of Maryland $ 52.3

University of California, Los Angeles $ 42.3

Arizona State University $ 39.0

University of Wisconsin-Madison $ 36.4

Georgia Institute of Technology $ 31.1

Brunette college $ 25.5

University of South Florida $ 25.4

_________

Some interesting models in these rankings are worth mentioning.

  • First, across the board, the majority of the top ten institutions are public universities.
  • In the various categories, the University of Michigan tops the list, reaching the top ten in five of the six social science fields.
  • Harvard University and Arizona State University made the top ten in three categories.
  • Five other institutions – Indiana University, Indiana University Purdue University (Indianapolis), New York University, University of California at Berkeley, and University of North Carolina – ranked in the top ten in two different areas.

_____________

Of course, the quality of research can be measured by other outcomes – publications in peer-reviewed journals, number of doctorates awarded, number of citations, scholarly awards, commercialization of intellectual property, and students’ post-graduation careers. . All of these measures are important indicators of impact.

But research expenditures have a particular value in judging the efforts and overall contributions of an institution to a field of research. Since the majority of funded grants are only distributed after a competitive process involving peer review, R&D spending indicates a consensus opinion on the value of the proposed research work.

Also, as Arizona State President Michael Crow observes, the wide range of institutions that conduct funded research is beneficial. “As the survey reveals, research on these topics is widely distributed in many types of institutions across the country. There is significant value in this type of distribution – it allows broad perspectives and new ideas to emerge in these important areas of research. “

Source link

]]>
Omicron, Moon, Mars and Lhc in 2022 Science https://scientific-library.net/omicron-moon-mars-and-lhc-in-2022-science/ Mon, 03 Jan 2022 07:46:37 +0000 https://scientific-library.net/omicron-moon-mars-and-lhc-in-2022-science/

Science 2022 will have to deal with the Omicron variant, for which much remains to be understood, and the developments of the Covid-19 pandemic, but it will also have to grapple with a return to the Moon and new life-search missions on March, while returning to a bigger race The world’s particle accelerator, the Large Hadron Collider (Lhc) at CERN in Geneva, after a technical failure, will spark new enthusiasm for the so-called new exploration. Physics. These are some of the key science designations for the New Year, which Nature has referenced on its website.

2022 marks the entry of the third year of the Covid-19 pandemic and the most urgent commitment, writes Nature, will be to answer the many questions that remain open about the Omicron variant. Among these, the most important is to understand whether it causes more or less serious illness. Additionally, protection against the potential emergence of new variants of SarsCoV2 is not expected to be reduced and the long-term effects of the disease, a condition called Long Covid, should continue to be studied.

However, the biggest challenge of the new year is to make vaccines available to all the world’s population, closing the current divide between rich and poor countries. Researchers around the world have repeatedly stressed that this is a critical step in limiting the spread of the virus. Among the vaccines, the first vaccines containing mRNA specific for SarsCoV2 variants, as well as new anti-Covid protein and DNA vaccines, are also expected.

2022 is also the year of the return to the moon, with the first Artemis missions and preparations to build the first lunar orbiting space station, Gateway. India’s new mission to the moon, Chandrayaan-3, is also planned, which aims to bring spacecraft to lunar soil. It is also the goal of the Japanese mission Slim, the Russian Luna 25, and Korea ready to make its debut on the moon, with the Korean Pathfinder Lunar Orbiter. The Japanese private company ispace is preparing to transfer the Emirati rover to the moon, while the American companies Astrobotic Technology and Intuitive Machines will bring NASA instruments to the lunar surface.

High expectations in 2022 also for missions to Mars, the most important of which are ExoMars, the European Space Agency (ESA) and Russia (Roscosmos), which will transport the Rosalind Franklin rover to the red planet in September, intended for search for traces of past life with a drill designed and manufactured in Italy.

As for physics, the Lhc accelerator will restart in June, after a prolonged technical failure also due to the pandemic. The two largest experiments, ATLAS and CMS, the same experiments that found the Higgs boson, have been optimized and will allow us to collect data on the 40 million proton collisions produced every second.

Source link

]]>
CD BioSignal Presents Diabetes and Metabolism Solutions for Life Science Research https://scientific-library.net/cd-biosignal-presents-diabetes-and-metabolism-solutions-for-life-science-research/ Fri, 24 Dec 2021 09:48:08 +0000 https://scientific-library.net/cd-biosignal-presents-diabetes-and-metabolism-solutions-for-life-science-research/

CD BioSignal, a US provider of life sciences and CRO research products, recently presented a comprehensive panel of research solutions covering all aspects of diabetes and metabolism and the study of metabolic diseases to provide the scientific community with a better and deeper understanding of metabolic regulation.

Metabolism describes the series of chemical reactions in a living system. The goals of metabolism are the conversion of nutrients into energy and building blocks, and the elimination of nitrogenous wastes. Metabolic processes are tightly controlled by cell signaling pathways to maintain metabolic homeostasis of the system. One of the hallmarks of cancer is altered metabolic patterns.

Metabolic pathways are a series of chemical reactions in metabolism, which are catalyzed by a sequence of enzymes. However, metabolic signaling pathways refer to the transductions of cell signaling that respond to the metabolic state and regulate cellular events to maintain cellular and organic homeostasis. Deregulation of these pathways is associated with metabolic diseases such as obesity, type 2 diabetes, as well as cancer and aging.

CD BioSignal now offers various solutions for research on metabolism, such as the identification of regulators to identify the regulators of genes participating in certain metabolic signaling pathways, the characterization of regulators to study the molecular function of certain regulators in the pathways of Metabolic signaling and the study of the mechanisms used to study the regulatory mechanism of certain regulators. Other solutions such as phenotype analysis, generation of animal models, chemical screening and development of therapies are also offered by CD BioSignal.

These new series of solutions can be used to study metabolic signaling pathways, such as the insulin signaling pathway, the mTOR pathway and the AMPK pathway. For example, the insulin signaling pathway, which signals transduction that regulates glucose homeostasis through the control of glucose and lipid metabolism. When insulin is released from the beta cells of the pancreas in response to high levels of nutrients, it binds to the insulin receptor, which activates signaling transduction and leads to cellular processes that promote absorption. glucose, fatty acids and amino acids.

Insulin resistance, where cells do not respond normally to insulin, is the underlying cause of type 2 diabetes. It also has a strong correlation with neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. With advanced technologies and dedicated scientists, CD BioSignal now provides its customers with research solutions to study the insulin signaling pathway and associated diseases.

“CD BioSignal is committed to meeting all your inquiries in the research of signaling pathways. We provide high quality reagents and complete solutions to support your innovative discoveries. These new products related to metabolism looking for solutions are economical, high-quality and hassle-free, and are available to our customers around the world. We guarantee to deliver our products and results on time, ”said Kristy J. Morris, Marketing Director at CD BioSignal.

Customers For more information on Diabetes and Metabolism Solutions, please visit CD BioSignal at https://www.cd-biosignal.com.

About CD BioSignal

CD BioSignal is a trusted research product provider and CRO based in New York City. With high quality reagents and comprehensive services, CD BioSignal is the one-stop-shop dedicated to researchers making advancements in studies of signaling pathways.

Source link

]]>
The global fluidics market for preclinical research, life sciences and clinical applications is expected to grow by $ 10.38 billion during the period 2021-2025, growing at a CAGR of 19.10% during the forecast period. https://scientific-library.net/the-global-fluidics-market-for-preclinical-research-life-sciences-and-clinical-applications-is-expected-to-grow-by-10-38-billion-during-the-period-2021-2025-growing-at-a-cagr-of-19-10-during-the-f/ Wed, 22 Dec 2021 14:11:00 +0000 https://scientific-library.net/the-global-fluidics-market-for-preclinical-research-life-sciences-and-clinical-applications-is-expected-to-grow-by-10-38-billion-during-the-period-2021-2025-growing-at-a-cagr-of-19-10-during-the-f/

Global Fluidics Market for Preclinical Research, Life Sciences, and Clinical Applications 2021-2025

New York, December 22, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Global Fluidics for Preclinical, Life Science Research, and Clinical Applications Market 2021-2025” – https://www.reportlinker.com/p05976133/?utm_source=GNW
38 billion during 2021-2025, increasing at a CAGR of 19.10% during the forecast period. Our Fluidics for Preclinical Research, Life Sciences, and Clinical Applications market report provides holistic analysis, market size and forecast, trends, growth drivers and challenges, as well as a supplier analysis covering approximately 25 suppliers.
The report offers up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases which are stimulating cellular research and various applications of fluidics technology. In addition, the increasing prevalence of chronic diseases leading to cell research is also expected to drive the market growth.
Fluidics for preclinical research, life sciences, and clinical applications market analysis includes product and end-user segments and geographic landscape.

The fluidics market for preclinical research, life sciences and clinical applications is segmented as follows:
By product
• Software and accessories
• Precision syringe pumps

By end user
• Industrial laboratories and CRO
• University and government research laboratories

By geographic landscape
• North America
• Europe
• Asia
• LINE

This study identifies the increase in R&D expenditure as one of the major reasons for the growth of the fluidics market for preclinical research, life sciences, and clinical applications over the coming years.

The analyst presents a detailed picture of the market through the study, synthesis and summation of data from multiple sources by analysis of key parameters. Our Fluidics Market Report for Preclinical Research, Life Sciences, and Clinical Applications covers the following areas:
• Fluidics for preclinical research, life sciences and clinical applications market size
• Fluidics market forecast for preclinical research, life sciences and clinical applications
• Fluidics for preclinical research, life sciences and clinical applications market industry analysis

This strong vendor analysis is designed to help customers improve their market position and as per this this report provides a detailed analysis of several leading vendors of Fluidic Products for Preclinical Research, Life Sciences, and Applications. clinics, including Advanced Microfluidics SA, BiosebLab, CETONI GmbH, Chemyx Inc., Halma Plc, Harvard Bioscience Inc., New Era Pump Systems Inc., Spetec GmbH, Stoelting Co. and World Precision Instruments. Additionally, the Fluidics for Preclinical Research, Life Sciences, and Clinical Applications market analysis report includes information on upcoming trends and challenges that will influence the market growth. It’s about helping businesses strategize and take advantage of any growth opportunities that lie ahead.
The study was conducted using an objective combination of primary and secondary information, including contributions from key industry participants. The report contains a comprehensive market and vendor landscape in addition to major vendor analysis.

The analyst presents a detailed picture of the market through the study, synthesis and summation of data from multiple sources through analysis of key parameters such as profit, price, competition and promotions. It presents various facets of the market by identifying the main influencers in the industry. The data presented is complete, reliable and the result of extensive research – both primary and secondary. Technavio’s market research reports provide a comprehensive competitive landscape along with in-depth vendor screening methodology and analysis using qualitative and quantitative research to forecast the precise growth of the market.
Read the full report: https://www.reportlinker.com/p05976133/?utm_source=GNW

On Report link
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
Source link

]]>
Fujifilm Renews Fellowship Fund at Harvard Medical School for Translational Science Research | News https://scientific-library.net/fujifilm-renews-fellowship-fund-at-harvard-medical-school-for-translational-science-research-news/ Mon, 20 Dec 2021 15:21:28 +0000 https://scientific-library.net/fujifilm-renews-fellowship-fund-at-harvard-medical-school-for-translational-science-research-news/

CAMBRIDGE, Mass., December 20, 2021 (GLOBE NEWSWIRE) – FUJIFILM Holdings America Corporation (Fujifilm) today announced that it has renewed its commitment to the Fujifilm Fellowship Fund at Harvard Medical School (HMS) to advance education and research in the field of translational medicine, the process of applying basic laboratory research to new therapeutic developments. The donation will support up to 8 additional doctorates. candidates for HMS until 2024.

Established in 2019, the scholarship program is designed to equip young scientists with the specialist skills needed to translate their research results into cutting-edge medical solutions for patients.

Harvard recently named Kailyn Doiron and Kanae Sasaki the latest Fujifilm Fellow recipients. They follow in the footsteps of 11 previous doctorates. HMS applicants who have been awarded the Fujifilm Fellowships, which provides two years of research funding to promising students from the nine HMS-based Life Sciences PhDs. programs. The HMS management selects all the beneficiaries of the program.

“Fujifilm’s strong and dynamic partnership with Harvard Medical School continues to thrive as we work diligently towards a common goal: the discovery and development of new therapies and treatments for a wide range of unmet medical needs,” said Yutaka Yamaguchi, Director General, Life Sciences. Business Division, Life Sciences Strategy Headquarters, FUJIFILM Corporation; President and CEO, FUJIFILM Irvine Scientific, Inc. “We extend our sincere congratulations to two highly esteemed doctoral students who recently received grants and whose work has the potential to change the lives of patients and their families. ”

Like all previous recipients, the last two Fujifilm Fellows represent the school’s most promising doctorate. students:

Kailyn Doiron is a third year doctoral student in Systems Biology, Synthetic and Quantitative. program. She has a background in cellular and molecular biology and a strong passion for research in synthetic biology. Kailyn works in the lab of Pamela Silver, Ph.D., Elliott T. and Onie H. Adams Professor of Biochemistry and Systems Biology at the Blavatnik Institute at HMS. As a member of the Silver Lab, Kailyn will continue to focus on bringing synthetic biology ideas to a place where they can be translated into transformative new drugs for patients. Ultimately, Kailyn strives to develop new protein therapies to address the unmet medical need for safe and effective treatments for chronic and inflammatory pain.

Kanae Sasaki is enrolled in a PhD in Biological and Biomedical Sciences. program. Previously, Kanae gained extensive research experience working as a research assistant throughout her undergraduate years, and later as a research technician at Massachusetts General Hospital in the Joung Lab. She is currently studying gene therapy for a degenerative retinal disease, retinitis pigmentosa (RP), in the lab of Constance Cepko, Ph.D., Bullard Professor of Genetics and Neuroscience at the Blavatnik Institute at HMS. Kanae’s goal is to develop gene therapies that prolong the survival of photoreceptor cells that can help patients with RP maintain sight and improve their quality of life.

“We are deeply grateful to the academic advisors of the Fujifilm Fellows for their guidance and mentorship in the pursuit of this potentially life-changing translational research,” commented Bruce E. Novich Sc.D., Division President, FUJIFILM Holdings America Corporation . “These scholarships are one of many life sciences partnership initiatives between Fujifilm and Harvard University, all of which continue to inspire us to NEVER STOP advancing the medical sciences. “

In addition to their doctorate. program, Fujifilm Fellows are enrolled in the Therapeutics Graduate Program, a new program focusing on pharmacology, toxicology and drug discovery. Here they receive rigorous multidisciplinary training to identify and develop new therapies, understand and study the mechanisms of action of drugs, analyze the reasons for clinical failures and develop new compounds and apply them in preclinical and clinical studies to improve the disease treatment.

About Fujifilm Fellowship The Fujifilm Fellowship program was designed by Fujifilm and HMS to advance translational medicine research by investing in the next generation of scientists. Selected beneficiaries who have been admitted to Harvard Medical School’s graduate program in therapeutics will receive financial assistance to continue their education and research in therapeutic innovation. The HMS management selects all the beneficiaries of the program. For more information, please visit https://www.fujifilmfellowship.com/ About Fujifilm FUJIFILM Holdings America Corporation is the regional headquarters for the Americas. It is made up of 21 affiliates in North America and Latin America that are engaged in the research, development, manufacture, sale and service of FUJIFILM products and services. The company’s portfolio represents a wide range of industries including medical and life sciences, electronics, chemistry, graphic arts, information systems, industrial products, broadcasting, media. recording and photography. For more information, please visit: https://www.fujifilm.com/us/en/about/region.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting-edge solutions to a wide range of global industries by leveraging its in-depth knowledge and foundational technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its broad portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the fiscal year ended March 31, 2021, the company achieved worldwide revenue of $ 21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible stewardship of the environment and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

### All product and company names mentioned in this document may be trademarks of their registered owners.

Christine Jackman FUJIFILM Holdings America Corporation 9142614959 christine.jackman@fujifilm.com

Copyright 2021 GlobeNewswire, Inc.

Source link

]]>
Fujifilm Renews Fellowship Fund at Harvard Medical School for Translational Science Research https://scientific-library.net/fujifilm-renews-fellowship-fund-at-harvard-medical-school-for-translational-science-research/ Mon, 20 Dec 2021 15:21:00 +0000 https://scientific-library.net/fujifilm-renews-fellowship-fund-at-harvard-medical-school-for-translational-science-research/

Fujifilm also congratulates the 2021 scholarship recipients

CAMBRIDGE, Mass., December 20, 2021 (GLOBE NEWSWIRE) – FUJIFILM Holdings America Corporation (Fujifilm) today announced that it has renewed its commitment to the Fujifilm Fellowship Fund at Harvard Medical School (HMS) to advance education and research in the field of translational medicine, the process of applying basic laboratory research to new therapeutic developments. The donation will support up to 8 additional doctorates. candidates for HMS until 2024.

Established in 2019, the scholarship program is designed to equip young scientists with the specialist skills needed to translate their research results into cutting-edge medical solutions for patients.

Harvard recently named Kailyn Doiron and Kanae Sasaki the latest Fujifilm Fellow recipients. They follow in the footsteps of 11 previous doctorates. HMS applicants who have been awarded the Fujifilm Fellowships, which provides two years of research funding to promising students from the nine HMS-based Life Sciences PhDs. programs. The HMS management selects all the beneficiaries of the program.

“Fujifilm’s strong and dynamic partnership with Harvard Medical School continues to thrive as we work diligently towards a common goal: the discovery and development of new therapies and treatments for a wide range of unmet medical needs,” said Yutaka Yamaguchi, Director General, Life Sciences. Business Division, Life Sciences Strategy Headquarters, FUJIFILM Corporation; President and CEO, FUJIFILM Irvine Scientific, Inc. “We extend our sincere congratulations to two highly esteemed doctoral students who recently received grants and whose work has the potential to change the lives of patients and their families. “

Like all previous recipients, the last two Fujifilm Fellows represent the school’s most promising doctorate. students:

Kailyn Doiron is a third year doctoral student in Systems Biology, Synthetic and Quantitative. program. She has a background in cellular and molecular biology and a strong passion for research in synthetic biology. Kailyn works in the lab of Pamela Silver, Ph.D., Elliott T. and Onie H. Adams Professor of Biochemistry and Systems Biology at the Blavatnik Institute at HMS. As a member of the Silver Lab, Kailyn will continue to focus on bringing synthetic biology ideas to a place where they can be translated into transformative new drugs for patients. Ultimately, Kailyn strives to develop new protein therapies to address the unmet medical need for safe and effective treatments for chronic and inflammatory pain.

Kanae Sasaki is enrolled in a PhD in Biological and Biomedical Sciences. program. Previously, Kanae gained extensive research experience working as a research assistant throughout her undergraduate years, and later as a research technician at Massachusetts General Hospital in the Joung Lab. She is currently studying gene therapy for a degenerative retinal disease, retinitis pigmentosa (RP), in the lab of Constance Cepko, Ph.D., Bullard Professor of Genetics and Neuroscience at the Blavatnik Institute at HMS. Kanae’s goal is to develop gene therapies that prolong photoreceptor cell survival and which can help RP patients maintain sight and improve their quality of life.

“We are deeply grateful to the academic advisors of the Fujifilm Fellows for their guidance and mentorship in the pursuit of this potentially life-changing translational research,” commented Bruce E. Novich Sc.D., Division President, FUJIFILM Holdings America Corporation . “These scholarships are one of many life sciences partnership initiatives between Fujifilm and Harvard University, all of which continue to inspire us to NEVER STOP advancing the medical sciences. “

In addition to their doctorate. program, Fujifilm Fellows are enrolled in the Therapeutics Graduate Program, a new program focusing on pharmacology, toxicology and drug discovery. Here they receive rigorous multidisciplinary training to identify and develop new therapies, understand and study the mechanisms of action of drugs, analyze the reasons for clinical failures and develop new compounds and apply them in preclinical and clinical studies to improve the disease treatment.

About the Fujifilm scholarship
The Fujifilm Fellowship Program was designed by Fujifilm and HMS to advance translational medicine research by investing in the next generation of scientists. Selected beneficiaries who have been admitted to Harvard Medical School’s graduate program in therapeutics will receive financial assistance to continue their education and research in therapeutic innovation. The HMS management selects all the beneficiaries of the program. For more information, please visit https://www.fujifilmfellowship.com/

About Fujifilm
FUJIFILM Holdings America Corporation is the regional headquarters for the Americas. It is made up of 21 affiliates in North America and Latin America that are engaged in the research, development, manufacture, sale and service of FUJIFILM products and services. The company’s portfolio represents a wide range of industries including medical and life sciences, electronics, chemistry, graphic arts, information systems, industrial products, broadcasting, media. recording and photography. For more information, please visit: https://www.fujifilm.com/us/en/about/region.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting-edge solutions to a wide range of global industries by leveraging its in-depth knowledge and foundational technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its broad portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the fiscal year ended March 31, 2021, the company achieved worldwide revenue of $ 21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible stewardship of the environment and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

###
All product and company names mentioned in this document may be trademarks of their registered owners.

CONTACT: Christine Jackman FUJIFILM Holdings America Corporation 9142614959 christine.jackman@fujifilm.com
Source link

]]>
Science, research and strengthening of the American market, keys to the future for Oryzon https://scientific-library.net/science-research-and-strengthening-of-the-american-market-keys-to-the-future-for-oryzon/ Thu, 16 Dec 2021 06:44:28 +0000 https://scientific-library.net/science-research-and-strengthening-of-the-american-market-keys-to-the-future-for-oryzon/

During the third quarter of 2021, at Oryzon, we maintained our traditional high investment rate, reaching 9.6 million euros in R&D, mainly for the clinical development of our iadademstat oncology and vafidemstat neurology programs.

Currently, the first of these is being evaluated in a phase II clinical trial (ALICE) investigating its use in patients with acute myeloid leukemia (AML) in combination with azacitidine and has recently completed recruitment. . Preliminary results from the 30-month study, presented at the EHA2021 conference last June, showed strong signs of clinical efficacy.

At the same time, we are preparing new iadademstat tests in AML and solid tumors. In AML, the company plans to initiate FRIDA, a Phase Ib / II multicenter study of iadademstat in combination with gilteritinib in patients with a refractory or relapsing FLT3 AML mutation. In small cell lung cancer (SCLC), the company is preparing the next trial, STELLAR, a multicentre randomized Phase Ib / II trial of iadademstat with an immune checkpoint inhibitor (ICI) in patients with SCLC metastatic in the first line. Both trials will be conducted in the United States and both plan to recruit around 120 patients.

On the other hand, we evaluate the vafidemstat in diseases of the nervous system. We currently have 2 phase IIb clinical trials in psychiatric illnesses underway. The PORTICO trial, which is already recruiting patients in Europe and the United States, will assess the efficacy of vafidemstat in patients with borderline personality disorder (BPD), with two main objectives: (i) reduction of blood pressure aggressiveness / restlessness and (ii) disease amelioration. Our other Phase IIb clinical trial is EVOLUTION, to assess the efficacy of vafidemstat on negative symptoms and cognition in patients with schizophrenia, which is being conducted in Spain and is also recruiting patients. Given the significant side effect profile of atypical antipsychotics used to treat schizophrenia, vafidemstat has enormous potential to be a safe, effective and well-tolerated treatment option for treating the underlying cognitive dysfunction and negative symptoms of schizophrenia. schizophrenia.

In addition, we are deploying a radically innovative approach to precision medicine with vafidemstat. The scientific community has shown that LSD1 inhibitors such as vafidemstat can offset the effects of a number of genetic failures that occur in certain nervous system disorders such as Kabuki syndrome (SK) and others. In collaboration with the world leaders in this disease, the company is preparing a Phase I / II clinical trial with vafidemstat in patients with KS. In addition, we have ongoing collaborations in the area of ​​precision medicine in autism with researchers at the Seaver Center for Autism Research and Treatment at the Icahn School of Medicine at Mount Sinai Hospital in New York and with the Institute of Medical and Molecular Genetics. (INGEMM) at La Paz University Hospital in Madrid, and in precision medicine in schizophrenia with researchers at Columbia University in New York.

Regarding our financial results, Oryzon maintains a significantly solid financial position as of September 30, 2021 with available financial resources amounting to € 30.9 million, which will allow us to pursue the development of our R&D activities and the development of our clinical studies. Likewise, this solidity is also reflected in the balance sheet at the end of September, which shows a relevant solidity with a net wealth of 73.3 million euros.

In the international environment, Oryzon maintains an increasingly important presence in the American market. In this context of progress and presence in the USA, we recently integrated in New York a new Global Business Director, Dr. Saikat Nandi, who benefits from a significant experience in the American capital markets and who will allow us to intensify our contacts with Wall Street and to strategically advance the business and achieve the next phase of Oryzon’s growth objectives. Dr Saikat will lead the strategic alliances that will define Oryzon’s portfolio going forward. His appointment means that the company’s medical and sales departments are led from the United States, which is part of Oryzon’s continued strategy to expand its presence there.

In short, despite the global impact produced by the coronavirus pandemic, Oryzon has continued to progress in its commercial strategy, as well as in the clinical development of its programs, helping to make Spain a benchmark in research and development. scientific innovation. The LOSS Salud de Vanguardia endowed with 1,469 million euros was recently presented, which pursues precisely as one of its main objectives to promote scientific research and to position Spain as a leading country in innovation and development of advanced therapies. In this context, Oryzon helps to demonstrate that in Spain there is pharmaceutical excellence and that the science is of the first order.

Source of the article

Disclaimer: This article is generated from the feed and not edited by our team.

Source link

]]>
Bruker: Mestrelab and ZONTAL Support Effective Life Sciences Research Using Advanced Analytical Data Management and Molecular Analysis Software Platform https://scientific-library.net/bruker-mestrelab-and-zontal-support-effective-life-sciences-research-using-advanced-analytical-data-management-and-molecular-analysis-software-platform/ Thu, 16 Dec 2021 05:29:04 +0000 https://scientific-library.net/bruker-mestrelab-and-zontal-support-effective-life-sciences-research-using-advanced-analytical-data-management-and-molecular-analysis-software-platform/

Press release

Mestrelab and ZONTAL support efficient life science research with advanced analytical data management and molecular analysis software platform

SAINT-JACQUES DE COMPOSTELLE, Spain – December 15, 2021 – Mestrelab, a leading chemistry and life science software company and ZONTAL, a leading analytical data center provider, have developed an innovative solution for management and analysis of analytical data that removes many previous hurdles. Developed for life science scientists, ZONTAL and Mestrelab software integration enables effective and efficient use of analytical molecular data.

Data management systems often limit search efficiency due to missing or complicated interfaces, redundant manual operations leading to underutilized data assets. ZONTAL and Mestrelab now provide the solution to these shortcomings with a powerful, advanced analytical data management and analysis system that integrates the several key features of both companies: digital collaboration, data standardization, compliance data integrity and workflow. automated analytics.

Through the integration of ZONTAL’s analytical data hub with Mestrelab’s analytical data assessment software, scientists using Mestrelab’s Mnova can now directly query, process and log data to and from the ZONTAL cloud. Additionally, data pipelines can be automated to enable scientists to perform spectral analysis in less time than it takes to get from their instrument to their desks.

Mestrelab and ZONTAL partnership will provide efficient workflows for better digital data management

Santiago Dominguez, CEO of Mestrelab

Partnership is in the essence of Mestrelab, and it was natural for us to consider partnering our solutions with an expert in the transformation, archiving and standardization of digital laboratory data to offer our end users common the best of both worlds. We strive to provide our users with easy access to data stored on the computing platform of their choice in a very intuitive way. In an age where AI and machine learning capabilities are key aspects of using data, our integrated offering will enable our customers to further leverage data in the AI ​​/ ML space.

Wolfgang Colsman, CEO of ZONTAL

The integration with Mestrelab is a natural extension of the value that ZONTAL Space brings to our customers in analytical chemistry. Vendor-independent data format for NMR, LC / GC-MS, UV, IR and other optical spectroscopy techniques removes barriers to integrating these key data assets into data streams. AI / ML work executed on the ZONTAL platform. Our clients are delighted to discover the value brought by this partnership.

Bruker is committed to expanding its cloud-based scientific software for customers in the chemical and pharmaceutical industries and to provide intuitive end-to-end solutions that make the analysis and extraction of knowledge in scientific research faster and easier. The integration of ZONTAL and Mestrelab is the next step in advanced data management, combining innovative data storage and analysis solutions to help scientists realize the full potential and use of their available data assets.

About Mestrelab Recherche

Mestrelab Research SL (Mestrelab), based in Santiago de Compostela, Spain, is an IT company that develops and markets scientific software solutions for analytical chemistry and laboratory computing in support of research, of development and manufacturing. Mestrelab’s solutions are used worldwide in the biopharmaceutical, chemical, agrochemical, food and beverage industries, as well as in other industries, academic institutions and government organizations. The offering also includes integration with existing IT systems and automated workflows of enterprise-level analytical laboratories. Mestrelab initially developed highly innovative solutions for analytical chemistry and, more specifically, for NMR and LC / GC-MS, and was, for almost a decade, the most widely used NMR processing solution. Mestrelab is majority owned by Bruker Corporation (Nasdaq: BRKR).

ZONTAL, headquartered in Melbourne, Florida, provides a leading analytical data center for the life science industry. We make digital transformation a reality by delivering breakthrough solutions to some of the most complex businesses. We reduce IT overheads, enable AI / ML applications, optimize time to market and increase compliance. Our clients celebrate our experience in the industry and our ability to provide highly intuitive solutions that empower scientists in their daily work. ZONTAL has offices in the United States, Europe and Asia. Together with our integration and service partners, ZONTAL supports our customers around the world.

Media contact (Bruker)

Thorsten thiel
VP Group Marketing
Bruker BioSpin
E: thorsten.thiel@bruker.com

Warning

Bruker Company published this content on December 15, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on December 16, 2021 05:28:03 AM UTC.

Public now 2021

All the news of BRUKER CORPORATION

Analyst Recommendations on BRUKER CORPORATION

Sales 2021 2,396 million

Net income 2021 281 million

Net debt 2021 151 million

PER 2021 ratio 43.9x
Yield 2021 0.20%
Capitalization 12,313 million
12,313 million
VE / Sales 2021 5.20x
VE / Sales 2022 4.83x
Number of employees 7,400
Free float 58.5%

Chart BRUKER CORPORATION
Duration :

Period :

Bruker Corporation Technical Analysis Chart |  MarketScreener

Trends in technical analysis BRUKER CORPORATION

Short term Mid Road Long term
Tendencies Neutral Neutral Bullish

Evolution of the income statement

To sell

To buy

Average consensus SURPASS
Number of analysts 11
Last closing price

$ 81.19

Average price target

$ 89.00

Spread / Average target 9.62%

Source link

]]>
Trinity Materials Science Research Projects Obtain European Innovation Council Funding https://scientific-library.net/trinity-materials-science-research-projects-obtain-european-innovation-council-funding/ Wed, 15 Dec 2021 11:11:00 +0000 https://scientific-library.net/trinity-materials-science-research-projects-obtain-european-innovation-council-funding/

The awards represent Trinity’s first success under Horizon Europe funding program

To print

To printTo print

Life

Read more: AMBER Horizon Europe is looking for Trinity

Two research projects coordinated by Principal Investigators at Trinity College Dublin and Amber, the Irelandentre Science Foundation for Advanced Materials Research and Bioengineering, have secured recommended funding from the European Innovation Council (EIC) via its very competitive Pathfinder Open competition. Both awards represent Trinity’s first successes in Horizon Europe, the EU’s key funding program for research and innovation.

The prizes have a total recommended fundraising value of over € 6million, of which around € 2million is expected to go to Trinity teams.

The funding will support the ThermoDust and SSLiP projects, which will allow the respective development of new innovative materials for use in additive manufacturing (ThermoDust) and in mechanical systems where a reduction in friction will extend the life of the machines and make them more efficient (SSLiP).

advertising

This project will allow researchers to solve a thermal management problem that is currently hampering countless industries. The team proposes to develop a radically new material – ThermoDust – with exceptional heat transport performance that will surpass current means of heat dissipation and have major impacts in ICT, electric vehicles and aerospace.

The team includes Dr Rocco Lupoi (assistant professor at Trinity’s School of Engineering; Amber and I-Form, the SFI research center for advanced manufacturing) as principal investigator; and Professors Valeria Nicolosi (Trinity School of Chemistry; Amber and I-Form) and Shuo Yin (Trinity School of Engineering) as co-investigators.

Dr Lupoi said: “There is a great need for innovative materials in many different industries, but thermal management is the big hurdle that needs to be overcome as material development is hampered by a relative lack of success in disposal. heat. For example, large data centers spend a considerable proportion of their total energy consumption to run their cooling systems, while the evolution of many electronic components is also hampered by the “thermal control problem”.

“We will use multidisciplinary techniques to develop a radically new material called ThermoDust and intend to showcase it with proof of concept applications in the electronics, electric vehicles and aerospace industries. Ultimately, we believe this project will establish Ireland and Europe as a leader in heat management and pave the way for countless new products and innovations that will be more efficient and sustainable than current alternatives. .

SSLiP: extending superlubrication to persistence

This project will see researchers take a recently discovered phenomenon called superlubrication – where atomic-sized solid 2D materials can slide over each other with virtually no friction – and scale it to macroscopic dimensions suitable for use. in manufacturing and transportation technology. Many powerful incentives exist to reduce friction in mechanical settings, with a significant reduction in power consumption and wear at the top of them.

The team includes Dr Graham Cross (associate professor at Trinity’s School of Physics and AMBER) as principal investigator; Prof Stefano Sanvito (professor of condensed matter theory at Trinity’s School of Physics and Amber); and Dr Zahra Gholamvand (Trinity’s School of Physics and Crann) as co-investigators.

“Reducing friction in mechanical systems will have a huge economic and societal impact,” said Dr. Cross. “Not only will the service life of conventional machines increase and their energy consumption will decrease, but it will also make possible the mechanical systems envisaged but not realized where the contact between the moving parts is currently suffering from force, wear and tear. excessive degradation. Examples of the latter could be machines in extreme temperature environments or the vacuum of outer space.

“It is estimated that a 20% reduction in friction in combustion engines will save 120 billion euros per year and will lead to a reduction in CO2 emissions of 290 million tonnes. This is essential for future technologies, as drastic improvements in energy efficiency and low-carbon CO2 emissions are key targets in most roadmaps for long-term sustainable transport. Overall, our work will leave its mark on the global sustainability journey and help us meet the challenges of the European Green Deal.

Linda Doyle, Vice President of Trinity College Dublin said: “These awards represent a huge success for the Trinity research community. The funding process is extremely competitive – only 6% of all applications from the last cycle were successful and only three awards were given to project coordinators in Ireland – meaning that only the best research proposals with the potential to ‘have significant societal impacts are accepted. -forward.

“We are very proud of Rocco and Graham, and their research teams, and look forward to seeing how these projects evolve. The research has the potential to have significant economic and sustainability impacts and will open doors to exciting future technologies. “

TechCentral Reporters

Read more: AMBER Horizon Europe is looking for Trinity



Source link

]]>
The top 10 most read science, research and technology articles in 2021 https://scientific-library.net/the-top-10-most-read-science-research-and-technology-articles-in-2021/ Tue, 14 Dec 2021 04:20:25 +0000 https://scientific-library.net/the-top-10-most-read-science-research-and-technology-articles-in-2021/

Covid-19 and Food Transmission: Meat, Dairy, Nuts, Fruits and Vegetables Potential Carriers, But Cannot Spread the Virus – Review

More studies are emerging on food products as a potential vector of SARS-CoV-2, the coronavirus that causes COVID-19, according to a review of research, but there is no evidence that it leads to transmissions.

China discovered the virus on most frozen foods imported from around 20 countries earlier in the pandemic, and the country has started to step up controls on inbound food imports and tighten its cold chain management in the hope of preventing a resurgence of COVID-19.

Researchers at Shahid Beheshti University of Medical Sciences of Iran said that although SARS-CoV-2 can be present in food and even food packaging, this does not necessarily mean that it is viable and capable of causing disease. infection.

In particular, laboratory studies have shown that SARS-CoV-2 remains very stable under refrigeration (4 ° C) and freezing (−10 to −80 ° C) conditions on fish, meat, poultry and pork skin, between 14 and 21 days.

“Biggest dairy breakthrough since pasteurization”: Australian company to launch nutrient-dense, high-digestibility dairy products this year

Australia-based Naturo is set to launch its high-nutrient, high-digestibility fresh dairy products, processed without pasteurization using world-leading technology that will also allow for extended shelf life.

According to Naturo Founder and CEO Jeff Hastings, Naturo will launch a line of nutrient-dense dairy products with high digestibility and long shelf life under the Wholey Milk Company brand.

“We will start by selecting retail outlets in Queensland before expanding production and sourcing nationally and then internationally in 2022,”Hastings said FoodNavigator-Asia.